Application Detail
Description of Medical Service
Susoctocog alfa is a treatment used to replace the missing protein needed for blood clotting (Factor VIII), which is less susceptible to being inhibited by autoantibodies than the patient’s own protein. This allows clotting to occur and assists to stop the bleeding. It also allows for the patient’s protein levels to be measured, to assist with guiding dosing and optimising treatment efficacy and safety.Description of Medical Condition
Acquired Haemophilia A is a condition where patients present with spontaneous bleeding despite no history of a bleeding disorder. Patients have the required protein needed for blood clotting, but autoantibodies develop to inhibit this normal function.Reason for Application
Referral from National Blood AuthorityMedical Service Type
TherapeuticPrevious Application Number/s
Not ApplicableAssociated Documentation
Application Form
Application Form (PDF 1169 KB)Application Form (Word 201 KB)
Consultation Survey
Consultation Survey (PDF 660 KB)Consultation Survey (Word 27 KB)
PASC Consultation
Expedited – Bypassing PASC
MSAC Consultation
MSAC consultation input closed Friday, 10 February 2023.
For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process
PICO Confirmation
-Assessment Report
-Public Summary Document
Public Summary Document (PDF 700 KB)Public Summary Document (Word 151 KB)